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It is recognized that a chronic low-grade inflammation and an activation of the immune 
system are involved in the pathogenesis of obesity-related insulin resistance and type 2 
diabetes. Systemic inflammatory markers are risk factors for the development of type 2 
diabetes and its macrovascular complications. Adipose tissue, liver, muscle and pancreas are 
themselves sites of inflammation in presence of obesity. An infiltration of macrophages and 
other immune cells is observed in these tissues associated with a cell population shift from an 
anti-inflammatory to a pro-inflammatory profile. These cells are crucial for the production of 
pro-inflammatory cytokines, which act in an autocrine and paracrine manner to interfere with 
insulin signaling in peripheral tissues or induce β-cell dysfunction and subsequent insulin 
deficiency. Particularly, the pro-inflammatory interleukin-1β is implicated in the pathogenesis 
of type 2 diabetes through the activation of the NLRP3 inflammasome. The objectives of this 
review are to expose recent data supporting the role of the immune system in the pathogenesis 
of insulin resistance and type 2 diabetes and to examine various mechanisms underlying this 
relationship. If type 2 diabetes is an inflammatory disease, anti-inflammarory therapies could 
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Obesity, in particular excess visceral adiposity, is associated with insulin resistance, 
hyperglycaemia, dyslipidaemia and hypertension, which together are termed “metabolic 
syndrome” [1]. These metabolic disorders increase the risk of development of type 2 diabetes 
mellitus (T2DM) and cardiovascular diseases and contribute to high rates of mortality and 
morbidity [1]. T2DM is the most prevalent metabolic disease in the world and is characterized 
by defects in insulin secretion and a peripheral insulin resistance in the skeletal muscle, the 
adipose tissue and the liver. The progression from obesity-related insulin resistance to T2DM 
remains poorly understood but implicates a failure of pancreatic β-cells to compensate for 
insulin resistance leading to chronic hyperglycaemia. A chronic low-grade inflammation and 
an activation of the immune system are observed in abdominal obesity and may have a role in 
the pathogenesis of obesity-related metabolic disorders [2-5]. This review summarizes data 
implicating the immune system in the pathophysiogy of insulin resistance and T2DM. We 
will also examine the biological, tissular and cellular inflammatory markers associated with 
obesity-related metabolic disorders that may predict the development of T2DM. Molecular 
mechanisms underlying this inflammatory activation state will be reviewed and preliminary 
results obtained with anti-inflammatory therapies in the prevention and treatment of T2DM 
will be described.  
 
 
1. SYSTEMIC MARKERS OF INFLAMMATION 
1.1. Inflammatory markers in obesity, metabolic syndrome and T2DM 
White blood cell counts and plasma levels of coagulation factors (fibrinogen and plasminogen 
activator inhibitor 1 (PAI-1)), acute-phase proteins such as C-reactive protein (CRP) and 
serum amyloid A (SAA), pro-inflammatory cytokines (tumor necrosis factor (TNF)-α, 
interleukin (IL)-1β and IL-6), and chemokines are elevated in obese and T2DM patients and 
shown to be reduced when these patients are engaged in a more intensive lifestyle causing 
weight loss [6-11]. These pro-inflammatory markers also positively correlated with insulin 
resistance and the features of the metabolic syndrome, in most cases, independently of the 
degree of obesity [6, 7, 12-14]. 
 










1.2. Inflammatory markers for development of T2DM in obese patients 
Subclinical chronic inflammation seems to be an independent risk factor for the development 
of T2DM. Indeed, high levels of many inflammatory factors at baseline in diverse human 
populations are correlated with incident T2DM, regardless of the initial degree of insulin 
resistance and obesity. Prospective studies have identified white blood cell count [12, 15], 
pro-inflammatory cytokines [16], chemokines [17], and other several indirect markers of 
inflammation such as fibrinogen, sialic acid and PAI-1 [15, 18] as predictors of T2DM. In 
contrast to all these inflammatory biomarkers, CRP measurement is less expensive, 
standardized and widely available. Particularly a highly sensitive measurement of CRP has 
been developed to detect this protein with greater accuracy at lower levels. A number of 
prospective studies have shown that high sensitivity-CRP (hs-CRP) levels predict 
development of T2DM in different non-diabetic populations regardless the degree of 
adiposity, fat distribution and insulin resistance. All these studies were included in a recent 
review and meta-analysis which provided further evidence that elevated CRP levels are 
significantly associated with increased risk of T2DM (relative risk [RR] 1.26 [95% 
confidence interval or CI 1.16-1.37]) [19]. This meta-analysis also detected a significant dose-
response association between IL-6 (its inducer) and T2DM risk (RR 1.31 [95% CI 1.17-1.46]) 
[19]. 
 
1.3. Inflammatory markers for cardiovascular disease in T2DM patients 
Since hs-CRP plasma levels have been associated with cardiovascular diseases and death in 
the general population [20] and in patients with metabolic syndrome [21], an important 
question is the possible association of inflammatory markers with these risks in T2DM 
patients. The Hoorn population-based study was the first to show that CRP is a predictor of 
mortality in T2DM individuals over a 5- to 7-year period [22]. Other observational studies in 
T2DM populations then showed that markers of inflammation and coagulation, and in 
particular CRP, are independent predictors of coronary heart disease [23, 24] and mortality 
[25]. However, the association between CRP and cardiovascular risk seems to be much 
weaker in T2DM patients than in the general population [24, 26] and needs to be more 
extensively studied. Interest has also been focused on cardiovascular risk prediction by pro-
inflammatory cytokines plasma levels. For instance, in the ADVANCE trial, IL-6 plasma 
levels significantly improved the prediction of macrovascular events and death in T2DM 
patients [27]. 
 










2. TISSUE INFLAMMATION IN OBESITY AND T2DM 
A number of experimental and clinical data have clearly established that adipose tissue, liver, 
muscle and pancreas are sites of inflammation in presence of obesity and T2DM. An 
infiltration of macrophages into these tissues is seen in animal models of obesity and diabetes 
as well as in obese human individuals with metabolic syndrome or T2DM. These cells are 
crucial for the production of pro-inflammatory cytokines [4], including TNFα, IL-6 and IL-
1β. They act in an autocrine and paracrine manner to promote insulin resistance by interfering 
with insulin signaling in peripheral tissues through activation of the c-JUN N-terminal kinase 
(JNK) and nuclear factor-kappa B (NF-κB) pathways [2]. These pathways are activated in 
multiple tissues in obesity and T2DM and have a central role in promoting tissue 
inflammation. 
 
2.1. Inflammation in insulin-sensitive tissues 
2.1.1 Adipose tissue 
Hotamisligil and colleagues were the first to show an increased expression and production of 
TNFα in adipose tissue of obese individuals and its direct role in obesity-induced insulin 
resistance [28]. Accumulating data then confirmed a specific up-regulation of genes encoding 
inflammatory factors and an over-production of many cytokines and chemokines in enlarged 
adipose tissue [5]. Furthermore, improvement in insulin sensitivity induced by weight loss 
was accompanied by a decrease in the expression of pro-inflammatory genes [28, 29]. So 
adipose tissue inflammation was considered as a crucial event leading to metabolic syndrome, 
T2DM and atherosclerotic cardiovascular diseases.  
More recently, adipose tissue has been associated with a marked accumulation of immune 
cells in its stromovascular fraction during obesity [4] (Figure 1). Particularly, obesity induces 
an infiltration of macrophages in adipose tissue of both mice and humans [30, 31]. Although it 
was shown that enlarged adipocytes themselves produce pro-inflammatory cytokines and 
chemokines [32], adipose tissue macrophages seem to be crucial for the production of adipose 
tissue-derived pro-inflammatory cytokines. Indeed, their recruitment correlates with the 
degree of obesity and is linked to systemic inflammation, insulin resistance [30] and 
metabolic syndrome [33]. Moreover, weight loss induced by surgery [29] or diet and exercise 
[10] results in a reduction in the number of adipose tissue macrophages in parallel to the 
decreased expression of pro-inflammatory markers in both adipose tissue and plasma of obese 
individuals.  










Macrophages can be classified into two distinct subtypes: the “classically activated 
macrophages” phenotype, termed M1, which secrete pro-inflammatory cytokines such as IL-
1β, IL-6, TNF-α, and the “alternatively activated macrophages” phenotype, termed M2 which 
produce anti-inflammatory cytokines such as IL-10 [4]. While well-established in mice [34, 
35], the existence of distinct M1 and M2 subsets of adipose tissue macrophages has not been 
confirmed in human, where macrophages have rather been described as being a mix between 
M1 and M2 phenotypes [36]. In addition to adipose tissue macrophages infiltration, obesity 
causes a phenotypic switch from the M2 to M1 phenotype, correlating with insulin resistance 
both in mice and humans [34-36]. Direct and paracrine signals issued from M1 macrophages 
can impair insulin signaling and adipogenesis in adipocytes whereas M2 macrophages seem 
to protect against obesity-induced insulin resistance [4].  
Although macrophages are the most abundant leukocyte population in expanding adipose 
tissue, the adaptive immune system may also contribute to obesity-induced inflammation. 
Infiltrating lymphocytes precede macrophage populations in obese adipose tissue concomitant 
with early insulin resistance and may play a role in adipose tissue inflammation by modifying 
the number and the activation state of adipose tissue macrophages [37-40]. In mouse models 
of obesity, an increased numbers of cytotoxic CD8+ effector cells is suspected to initiate the 
recruitment and activation of adipose tissue macrophages and promote pro-inflammatory 
cascades associated with insulin resistance [38, 40]. Obesity also induces modification in the 
balance between pro-inflammatory (T helper 1 and T helper 17 lymphocytes) and anti-
inflammatory (T helper 2 and regulatory T lymphocytes) CD4+ cells subsets, leading to 
secretion of cytokines from newly recruited adipose tissue macrophages [39-41]. Of particular 
interest, the number of anti-inflammatory regulatory T lymphocytes decreases with obesity in 
adipose tissue of both mice and humans [37, 39, 40] and even more in obese patients with 
metabolic syndrome [33]. The regulatory T lymphocytes express high amount of the anti-
inflammatory cytokine IL-10 which inhibit macrophage migration and induce the 
differentiation of M2 macrophages [35, 37]. A boost in the number of these cells in obese 
mice can improve insulin sensitivity and reduce macrophage infiltration in adipose tissue [37]. 
These data suggest that regulatory T cells may repress adipose tissue inflammation and play a 
role in providing protection against  insulin resistance-induced inflammation linked to obesity 
[33, 37]. The number of many other immune cells is also modified in adipose tissue during 
obesity and could regulate inflammation and insulin resistance[4] (Figure 1).  
Overall, these data reveal a complex interplay between cells of innate and adaptive immunity 
and the balance among these immune cells appears to be important for the homeostasis and 










control of adipose tissue inflammation in obesity and T2DM. However, the molecular events 
that initiate immune cell recruitment and activation are not fully understood. 
 
Subcutaneous versus visceral adipose tissues 
Abdominal obesity is the key component of the metabolic syndrome, with a predominance of 
intra-abdominal visceral fat accumulation, indirectly measured by waist circumference in 
clinical practice. So, besides total adiposity, the pathogenic role of adipose tissue seems to be 
determined by its specific anatomic location. Indeed, although both subcutaneous and visceral 
adipose tissues are associated with metabolic risk profile, high visceral adipose tissue is more 
strongly correlated with metabolic syndrome than its subcutaneous counterpart[42]. 
Furthermore, it is associated with ectopic lipid accumulation in the liver and skeletal muscle, 
which participates to local insulin resistance and contributes to associated metabolic 
complications [43]. Subcutaneous and visceral adipose tissues differ by phenotypic, 
physiological and functional characteristics [43]. Specific differences in inflammatory profile 
have also been reported, with more macrophages [29, 31, 33], T lymphocytes [31, 33], and 
inflammatory molecules in the visceral vs the subcutaneous tissues of obese individuals [29, 
33]. Moreover, a lower number of anti-inflammatory regulatory T lymphocytes was recently 
found in the visceral adipose tissue of obese individuals with metabolic syndrome [33]. This 
less favourable inflammatory profile of visceral adipose tissue is in line with the belief this 
tissue has a more important role in the development of obesity-related insulin resistance.  
 
2.1.2 Liver 
Nonalcoholic fatty liver disease (NAFLD) often accompanies abdominal obesity, and its 
prevalence increases in parallel to that of T2DM. NAFLD includes a large spectrum of 
lesions, from simple benign steatosis to steatohepatitis (nonalcoholic steatohepatitis or 
NASH), which can lead to cirrhosis and hepatocarcinoma [44]. Inflammation clearly plays a 
pivotal role in the progression of this disease process. NAFLD and subsequent hepatic insulin 
resistance in obesity are associated with increased expression and overproduction of 
inflammatory mediators, including TNFα, IL-6 and IL-1β [45]. Unlike adipose tissue, the 
liver is densely populated with resident macrophages, the Kupffer cells, which account for 
over 10% of total liver cells. The number of Kupffer cells does not increase with obesity, but 
their activation state changes [45, 46]. Although Kupffer cells have been less studied than 
adipose tissue macrophages in the context of insulin resistance, they clearly contribute to the 










production of inflammatory mediators that promote insulin resistance in liver [46]. 
Interestingly, as earlier described for adipose tissue macrophages, alternative M2 activation 
phenotype of Kupffer cells appears to ameliorate insulin resistance and to delay the 
progression to NASH in mice [46]. These data suggest that steatosis might induce a sub-acute 
inflammatory response in liver, similar to that observed in the adipose tissue inflammation 
following adipocyte lipid accumulation. Alternatively, pro-inflammatory mediators in the 




The muscle is another major site of insulin resistance in obesity and T2DM. Recent reports 
have shown an infiltration of macrophages within skeletal muscles of obese mice, particularly 
in the inter-muscular adipose depots [30]. Just as adipose tiss e, these skeletal muscle 
macrophages exhibit a pro-inflammatory M1 phenotype [47] accompanied with an increased 
expression of inflammatory factors in muscle cells [30, 47]  contributing locally to insulin 
resistance. Moreover, the gene expression of phenotype markers of pro- and anti-
inflammatory macrophages in human skeletal muscle seems to correlate with insulin 
sensitivity [48]. However, the content of macrophages in skeletal muscle in obesity is by far 
lower than in adipose tissue or liver, and further research is needed to determine if skeletal 
muscle is mainly a target of inflammation-induced insulin resistance or if local inflammatory 
cascades may also play a role in insulin resistance. 
 
2.2. INFLAMMATION IN PANCREAS AND INSULIN DEFICIENCY 
The progression from obesity-related insulin resistance to T2DM implicates a failure of 
pancreatic β cells to compensate for insulin resistance, leading to chronic hyperglycaemia. An 
inflammation was also demonstrated in pancreatic islets of T2DM patients as shown by the 
presence of amyloid deposits, fibrosis, increased β cell death and infiltration of macrophages 
along with increased levels of pro-inflammatory cytokines and chemokines [3]. Moreover this 
increase of immune cells in pancreatic islets is described before the onset of T2DM. 
Particularly the expression and local release of the pro-inflammatory cytokine IL-1β are 
increased in pancreatic islet of T2DM individuals [49]. This cytokine seems to be a master 
regulator of islet inflammation in T2DM by increasing local expression of pro-inflammatory 
cytokines and chemokines [50] leading to immune cell recruitment in islets. This local 










inflammation can reduce insulin secretion and trigger β-cell apoptosis leading to decrease islet 
mass, all critical events in the progression of T2DM.  
 
3. SENSORS AND MEDIATORS OF INFLAMMATION IN OBESITY 
AND T2DM 
Although subclinical inflammation is important in the pathogenesis of T2DM, the events 
initiating this inflammatory process remain unclear and could involve different but synergic 
mechanisms leading to the activation of NF-κB and JNK pathways, cytokines and 
chemokines release and recruitment of immune cells. 
 
3.1. IL-1β and NLRP3 inflammasome 
IL-1β, one of the major pro-inflammatory cytokine produced by macrophages, has been 
shown to be a key contributor to the pathogenesis of T2DM. IL-1β signaling occurs through 
the IL-1 receptor-I and leads to the activation of NF-κB pathways and the generation of other 
inflammatory mediators, such as TNFα and IL-1β itself, thus initiating a self-amplifying 
cytokine network [50]. The control of IL-1β production is tightly regulated and depends on 
two signals. First, a pro-inflammatory signal stimulates the transcription of IL1B with 
subsequent storage of inactive pro-IL-1β into the cell. A second signal then induces the 
production of active, mature IL-1β by cleavage of its inactive precursor by caspase-1, which 
is activated in a large cytoplasmic multiprotein complex called the inflammasome [51]. 
Inflammasomes are central components of the innate immune response and recognize 
microbial products (pathogen-associated molecular patterns (PAMPs)) or endogenous 
molecules (danger-associated molecular pattern (DAMPs)) by innate pattern recognition 
receptors (PRRs). Structurally, inflammasomes are usually formed through the interaction 
between a PRR, mainly a member of the nucleotide-binding oligomerization domain like 
receptor (NLR) family, the adaptor protein apoptosis-associated speck-like protein containing 
a caspase-recruitment domain (ASC) and the pro-caspase-1 [51]. Among several NLRs that 
form inflammasome platforms, there are compelling evidences for a major role of the NLR 
family pyrin domain-containing 3 (NLRP3) inflammasome in the progression from obesity to 
T2DM (Figure 2). NLRP3 inflammasome activation and subsequent IL-1β production have 
been first described in pancreatic β-cells and islet-infiltrating macrophages. They contribute to 
islet inflammation induced by chronic exposure to high levels of free fatty acids and glucose, 
leading to increased apoptosis and impaired insulin secretion of β-cells [49, 52, 53]. 










Moreover, islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the 
pancreas, seems to contribute to IL-1β production in islets through activation of the NLRP3 
inflammasome [54].  
Accumulating evidences also give to NLRP3 inflammasome a central role in obesity-induced 
insulin resistance [33, 55, 56]. The expression of NLRP3 inflammasome components, the 
activity of caspase-1 and the levels of IL-1β are increased in adipose tissue, mainly in 
macrophages, of obese mice and humans and directly correlate with insulin resistance, 
features of the metabolic syndrome and severity of T2DM [33, 56]. The deleterious effects of 
visceral adipose tissue might be also related to an up-regulated expression and activation of 
NLRP3 inflammasome compared to subcutaneous adipose tissue in overweight and obese 
patients [33, 57]. The NLRP3 inflammasome seems to act as a sensor of metabolic danger 
signals that accumulate during obesity, including high levels of glucose [52], saturated free 
fatty acids [58, 59], lipid intermediates such as ceramides [56] and uric acid [51], and its 
activation results in IL-1β production and induction of numerous cytokines and chemokines. 
Moreover its inhibition has shown to have pleiotropic effects combining improved insulin 
signaling in adipose tissue, liver and skeletal muscle, and increased insulin secretion in the 
pancreas [55, 56]. 
We have recently strengthened the involvement of NLRP3 inflammasome in obesity-related 
metabolic disorders by studying several features related to NLRP3 inflammasome activation 
in a unique subgroup of obese individuals who not display the typical metabolic disorders 
associated with obesity despite their excessive fatness, and are at lower risk of developing 
T2DM and cardiovascular diseases. This phenotype is referred in the literature as 
“metabolically healthy obesity” (MHO) and may account for around 30% of the obese 
population [60]. Interestingly, the MHO phenotype is characterized by a more favourable 
body fat distribution with lower visceral fat and greater subcutaneous fat [42], by a lower 
ectopic fat depot in the liver [61], and by a less inflammatory profile with lower levels of 
circulating inflammatory markers [14, 42] compared to unhealthy obese phenotype. We have 
recently reported that the visceral adipose tissue of MHO phenotype is associated with lower 
activation of the NLRP3 inflammasome in infiltrating macrophages, and with a more 
favourable inflammatory and immunological profile compared to that of unhealthy obese 
phenotype [33] (Figure 3). Identification of the triggers that determine differential activation 
of the inflammasome between obesity phenotypes would likely help to better understand the 
physiopathology of obesity-related metabolic disorders. Fatty acids may be good candidates 
as saturated fatty acid can induce inflammatory cascades in macrophages and adipocytes 










through the activation of NLRP3 inflammasome [58] whereas unsaturated fatty acids exert 
strong anti-inflammatory effects resulting in improved insulin sensitivity in obese and T2DM 
individuals [62]. Moreover, unsaturated and omega-3 fatty acids do not activate NLRP3 
inflammasome [58, 59, 63] and can prevent its activation by other inducers [59]. The 
importance of unsaturated fatty acids in mediating inflammation is enhanced by a recent study 
showing a distinct fatty acid profile between MHO and unhealthy obese individuals, 
specifically for saturated fatty acids [64]. Further comparisons of these two groups are 
required to better identify potential mechanisms of protection against obesity-related insulin 
resistance and inflammation and to develop preventive and therapeutic strategies.  
 
3.2. Adipocyte hypertrophy, hypoxia and cell death 
Other hypothetical events have been proposed to initiate inflammatory process in adipose 
tissue. Obesity leads to an increased adipocyte size and hypertrophic adipocytes may produce 
themselves cytokines and chemokines [32], leading to macrophages recruitment. Adipocyte 
hypertrophy may also be responsible for hypoxia or even adipocyte death. Areas of hypoxia 
have been observed in expanding adipose tissue of obese mice and humans, as a result of 
insufficient vasculature and oxygen supply. Hypoxia can induce recruitment of macrophages 
and expression of pro-inflammatory cytokines in both adipocytes and immune cells, 
contributing to adipose tissue inflammation and dysfunction [31]. In the absence of additional 
nutrients supply, hypertrophy can also provoke adipocyte necrosis and the release of their 
cellular contents into the extracellular space triggering an inflammatory response. 
Particularly, some of the moribund or dead adipocytes become surrounded by macrophages to 
form the “crown-like structures” observed in expanding adipose tissue [29-31]. 
 
3.3. Endoplasmic reticulum stress 
One other potential mechanism of NLRP3 activation in macrophages involves the 
endoplasmic reticulum, a major site for protein folding, maturation and trafficking. In obesity, 
the chronic excess nutrient intake generates endoplasmic reticulum stress due to an increase in 
synthetic demand, leading to activation of pro-inflammatory signaling pathways. Endoplasmic 
reticulum stress has been shown in adipose tissue of obese insulin resistant individuals and 
may be a cause for the development of insulin resistance and inflammation [65].  
 










4. ANTI-INFLAMMATORY THERAPEUTIC PERSPECTIVES  
Given the obvious link between inflammation and pathogenesis of T2DM, anti-inflammatory 




Considering the central role of NLRP3 inflammasome and IL-1β in the pathogenesis of 
T2DM, it is not surprising that the blockade of IL-1β activity has shown improvement in 
glucose control in prediabetic or T2DM populations. Studies conducted with IL-1 receptor 
antagonist (anakinra) or IL-1β antagonism (gevokizumab, canakizumab and LY2189102) 
have shown beneficial effects on glycated haemoglobin and β cell function in parallel to a 
decrease in systemic markers of inflammation [67-70]. Moreover, two studies have 
demonstrated persistent effects up to several weeks after treatment cessation with anakinra 
[71] or anti- IL-1β antibody [70]. Although the short duration of these studies does not 
provide definitive conclusions, data suggests that IL-1β blocking activity enhances glucose 
control in diabetic patients by improving the β-cell function and may even allow a partial 
generation these cells.  
 
4.2. Salicylate and salsalate 
Sodium salicylate and aspirin have demonstrated beneficial effects in the treatment of T2DM 
by improving glycaemic control through inhibition of NF-κB activity [72, 73]. Salsalate, 
prodrug of salicylate, which unlike aspirin and sodium salicylate does not lead to bleeding 
risk, can improve insulin sensitivity and glucose control in prediabetic and T2DM patients 
with a good safety profile [74, 75]. More particularly, a large randomized trial, the Targeting 
Inflammation with Salsalate in Type 2 Diabetes (TINSAL-T2D) trial, concluded that salsalate 
improves glucose control in T2DM patients with decrease in fasting glucose and glycated 
haemoglobin levels and enhances lipid profile [75]. These data suggest that NF-κB pathways 
may represent a novel therapeutic target for prevention and treatment of T2DM. More 
extensive studies are needed to confirm whether effects are sustainable with continued 
administration of these drugs. 
 











TNFα was the first pro-inflammatory cytokine implicated in pathogenesis of obesity-related 
insulin resistance and T2DM [28]. However, TNF-α antagonism has not demonstrated 
significant improvement on insulin sensitivity in patients with metabolic syndrome [76] or 
T2DM [77, 78], but these pilot studies were probably underpowered as they were conducted 
on a short-time period in a limited number of patients. Further longer and bigger studies are 
warranted, especially because TNF-α antagonism treatment in non-diabetic patients with 




The concept of T2DM as an inflammatory disease has recently emerged and seems to be 
confirmed by accumulating evidences. A number of studies have shown that abdominal 
obesity is associated with systemic low grade inflammation leading to insulin resistance and 
metabolic disorders. Moreover, systemic inflammatory markers can predict development of 
T2DM and cardiovascular diseases in the general population, and should be therefore used 
more widely in clinical practice to detect individuals at risk. Adipose tissue appears to play a 
central role in the induction of inflammation as over-nutrition leads to changes in its cellular 
composition and production of pro-inflammatory cytokines and chemokines. A local 
inflammation is also observed in the liver and skeletal muscle but its role in obesity-related 
metabolic disorders still needs to be determined. Recent evidence implicates the 
inflammasome NLRP3 in the pathogenesis of metabolic syndrome and T2DM. In pancreas 
activation of NLRP3 inflammasome by high levels of glucose and fatty acids and subsequent 
release of IL-1β lead to β cells dysfunction and apoptosis, insulin deficiency and progression 
to T2DM. NLRP3 inflammasome is also activated in macrophages infiltrating visceral 
adipose tissue from obese patients with metabolic disorders, and contributes to local 
inflammation, defect in adipogenesis and insulin resistance. The exact events and triggers that 
promote inflammatory cascade activation still need to be determined. Because an imbalance 
in inflammatory profile and inflammasome activation has been detected in visceral adipose 
tissue of metabolically healthy and unhealthy obese persons, study of these phenotypes may 
help to better understand the molecular mechanisms, identify signal dangers in obesity and 
develop preventive and therapeutic strategies. Targeting inflammation, especially NLRP3 
inflammasome, may offer potential novel therapeutic perspectives in T2DM prevention and 
treatment.  











Conflict of Interest Statement 
None 
  











[1] Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 
Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes 
Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood 
Institute; American Heart Association; World Heart Federation; International Atherosclerosis 
Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-
5. 
[2] Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 
2006;116:1793-801. 
[3] Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 
2011;11:98-107. 
[4] Chawla A, Nguyen KD, Goh YP. Macrophage-mediated inflammation in metabolic 
disease. Nat Rev Immunol. 2011;11:738-49. 
[5] Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic 
disease. Nat Rev Immunol. 2011;11:85-97. 
[6] Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune 
system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. 
Diabetologia. 1997;40:1286-92. 
[7] Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: 
associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for 
cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972-8. 
[8] Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, et al. Elevated levels of 
interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after 
weight loss. J Clin Endocrinol Metab. 2000;85:3338-42. 
[9] Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, et al. Intensive 
lifestyle intervention or metformin on inflammation and coagulation in participants with 
impaired glucose tolerance. Diabetes. 2005;54:1566-72. 
[10] Bruun JM, Helge JW, Richelsen B, Stallknecht B. Diet and exercise reduce low-grade 
inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in 
severely obese subjects. Am J Physiol Endocrinol Metab. 2006;290:E961-7. 
[11] Belalcazar LM, Haffner SM, Lang W, Hoogeveen RC, Rushing J, Schwenke DC, et al. 
Lifestyle intervention and/or statins for the reduction of C-reactive protein in type 2 diabetes: 
from the look AHEAD study. Obesity. 2013;21:944-50. 
[12] Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white 
blood cell count is associated with a worsening of insulin sensitivity and predicts the 
development of type 2 diabetes. Diabetes. 2002;51:455-61. 
[13] Natali A, Toschi E, Baldeweg S, Ciociaro D, Favilla S, Sacca L, et al. Clustering of 
insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. 
Diabetes. 2006;55:1133-40. 
[14] Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and 
nonobese adults? J Clin Endocrinol Metab. 2013;98:E1610-9. 
[15] Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-
grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk 
in communities study. Diabetes. 2003;52:1799-805. 
[16] Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, et al. 
Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective 
population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-
Potsdam Study. Diabetes. 2003;52:812-7. 










[17] Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C, et al. Chemokines 
as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984-
2002. Diabetologia. 2006;49:921-9. 
[18] Festa A, D'Agostino R, Jr., Tracy RP, Haffner SM, Insulin Resistance Atherosclerosis S. 
Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the 
development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 
2002;51:1131-7. 
[19] Wang X, Bao W, Liu J, Ouyang YY, Wang D, Rong S, et al. Inflammatory markers and 
risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care. 2013;36:166-
75. 
[20] Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J 
Intern Med. 2002;252:283-94. 
[21] Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, 
and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy 
American women. Circulation. 2003;107:391-7. 
[22] Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, et al. von 
Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic 
subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol. 1999;19:3071-8. 
[23] Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. 
Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: 
the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med. 2000;133:81-91. 
[24] Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, et al. C-reactive protein as a 
predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong 
Heart Study. Circulation. 2005;112:1289-95. 
[25] Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T. High-sensitivity C-reactive 
protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-
up study. Diabetes Care. 2006;29:329-33. 
[26] Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-
reactive protein with cardiovascular disease mortality according to diabetes status: pooled 
analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care. 
2012;35:396-403. 
[27] Lowe G, Woodward M, Hillis G, Rumley A, Li Q, Harrap S, et al. Circulating 
inflammatory markers and the risk of vascular complications and mortality in people with 
type 2 diabetes and cardiovascular disease or risk factors: The ADVANCE Study. Diabetes. 
2014;63:1115-23. 
[28] Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose 
tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J 
Clin Invest. 1995;95:2409-15. 
[29] Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, et al. Reduction of 
macrophage infiltration and chemoattractant gene expression changes in white adipose tissue 
of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005;54:2277-86. 
[30] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, Jr. Obesity 
is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796-
808. 
[31] O'Rourke RW, White AE, Metcalf MD, Olivas AS, Mitra P, Larison WG, et al. Hypoxia-
induced inflammatory cytokine secretion in human adipose tissue stromovascular cells. 
Diabetologia. 2011;54:1480-90. 
[32] Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and 
adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92:1023-33. 










[33] Esser N, L'Homme L, De Roover A, Kohnen L, Scheen AJ, Moutschen M, et al. Obesity 
phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral 
adipose tissue. Diabetologia. 2013;56:2487-97. 
[34] Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose 
tissue macrophage polarization. J Clin Invest. 2007;117:175-84. 
[35] Fujisaka S, Usui I, Bukhari A, Ikutani M, Oya T, Kanatani Y, et al. Regulatory 
mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice. 
Diabetes. 2009;58:2574-82. 
[36] Wentworth JM, Naselli G, Brown WA, Doyle L, Phipson B, Smyth GK, et al. Pro-
inflammatory CD11c+CD206+ adipose tissue macrophages are associated with insulin 
resistance in human obesity. Diabetes. 2010;59:1648-56. 
[37] Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, 
fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. 
Nat Med. 2009;15:930-9. 
[38] Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ 
effector T cells contribute to macrophage recruitment and adipose tissue inflammation in 
obesity. Nat Med. 2009;15:914-20. 
[39] Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, et al. Normalization of 
obesity-associated insulin resistance through immunotherapy. Nat Med. 2009;15:921-9. 
[40] Deiuliis J, Shah Z, Shah N, Needleman B, Mikami D, Narula V, et al. Visceral adipose 
inflammation in obesity is associated with critical alterations in tregulatory cell numbers. 
PLoS One. 2011;6:e16376. 
[41] Jagannathan-Bogdan M, McDonnell ME, Shin H, Rehman Q, Hasturk H, Apovian CM, 
et al. Elevated proinflammatory cytokine production by a skewed T cell compartment requires 
monocytes and promotes inflammation in type 2 diabetes. Journal of immunology. 
2011;186:1162-72. 
[42] Koster A, Stenholm S, Alley DE, Kim LJ, Simonsick EM, Kanaya AM, et al. Body fat 
distribution and inflammation among obese older adults with and without metabolic 
syndrome. Obesity. 2010;18:2354-61. 
[43] Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol 
Rev. 2013;93:359-404. 
[44] Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical 
aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008;34:634-7. 
[45] Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic 
insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 
2005;11:183-90. 
[46] Huang W, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, et al. Depletion of 
liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin 
resistance. Diabetes. 2010;59:347-57. 
[47] Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, et al. A 
subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free 
fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem. 
2007;282:35279-92. 
[48] Fink LN, Oberbach A, Costford SR, Chan KL, Sams A, Bluher M, et al. Expression of 
anti-inflammatory macrophage genes within skeletal muscle correlates with insulin sensitivity 
in human obesity and type 2 diabetes. Diabetologia. 2013;56:1623-8. 
[49] Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. 
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human 
pancreatic islets. J Clin Invest. 2002;110:851-60. 










[50] Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. 
Annu Rev Immunol. 2009;27:519-50. 
[51] Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic 
danger? Science. 2010;327:296-300. 
[52] Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links 
oxidative stress to inflammasome activation. Nat Immunol. 2010;11:136-40. 
[53] Boni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, Prazak R, et al. Free 
fatty acids induce a proinflammatory response in islets via the abundantly expressed 
interleukin-1 receptor I. Endocrinology. 2009;150:5218-29. 
[54] Masters SL, Dunne A, Subramanian SL, Hull RL, Tannahill GM, Sharp FA, et al. 
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism 
for enhanced IL-1beta in type 2 diabetes. Nat Immunol. 2010;11:897-904. 
[55] Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, et al. 
Inflammasome is a central player in the induction of obesity and insulin resistance. Proc Natl 
Acad Sci U S A. 2011;108:15324-9. 
[56] Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. The 
NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat 
Med. 2011;17:179-88. 
[57] Koenen TB, Stienstra R, van Tits LJ, Joosten LA, van Velzen JF, Hijmans A, et al. The 
inflammasome and caspase-1 activation: a new mechanism underlying increased 
inflammatory activity in human visceral adipose tissue. Endocrinology. 2011;152:3769-78. 
[58] Wen H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, et al. Fatty acid-induced NLRP3-
ASC inflammasome activation interferes with insulin signaling. Nat Immunol. 2011;12:408-
15. 
[59] L'Homme L, Esser N, Riva L, Scheen A, Paquot N, Piette J, et al. Unsaturated fatty acids 
prevent activation of NLRP3 inflammasome in human monocytes/macrophages. J Lipid Res. 
2013;54:2998-3008. 
[60] Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, et al. 
The obese without cardiometabolic risk factor clustering and the normal weight with 
cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the 
US population (NHANES 1999-2004). Arch Intern Med. 2008;168:1617-24. 
[61] Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, et al. Identification 
and characterization of metabolically benign obesity in humans. Arch Intern Med. 
2008;168:1609-16. 
[62] Summers LK, Fielding BA, Bradshaw HA, Ilic V, Beysen C, Clark ML, et al. 
Substituting dietary saturated fat with polyunsaturated fat changes abdominal fat distribution 
and improves insulin sensitivity. Diabetologia. 2002;45:369-77. 
[63] Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, Bourquin C, et al. Omega-3 fatty 
acids prevent inflammation and metabolic disorder through inhibition of NLRP3 
inflammasome activation. Immunity. 2013;38:1154-63. 
[64] Perreault M, Zulyniak MA, Badoud F, Stephenson S, Badawi A, Buchholz A, et al. A 
distinct Fatty Acid profile underlies the reduced inflammatory state of metabolically healthy 
obese individuals. PLoS One. 2014;9:e88539. 
[65] Cnop M, Foufelle F, Velloso LA. Endoplasmic reticulum stress, obesity and diabetes. 
Trends Mol Med. 2012;18:59-68. 
[66] Esser N, Paquot N, Scheen A. Anti-inflammatory agents to treat or prevent type 2 
diabetes, metabolic syndrome and cardiovascular disease. Expert opinion on investigational 
drugs. 2014. In press 
[67] Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-
receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356:1517-26. 










[68] Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, et al. Effects of 
interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, 
interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation. 
2012;126:2739-48. 
[69] Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, et 
al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. 
Diabetes Care. 2012;35:1654-62. 
[70] Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, et al. 
Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of 
subcutaneous LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. 
Diabetes Care. 2013;36:2239-46. 
[71] Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. 
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes 
Care. 2009;32:1663-8. 
[72] Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, et al. Reversal of 
obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. 
Science. 2001;293:1673-7. 
[73] Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, et al. 
Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J 
Clin Invest. 2002;109:1321-6. 
[74] Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, et al. The effect of 
salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a 
randomised double-blind placebo-controlled study. Diabetologia. 2009;52:385-93. 
[75] Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE, et al. The 
effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. 
Ann Intern Med. 2010;152:346-57. 
[76] Paquot N, Castillo MJ, Lefebvre PJ, Scheen AJ. No increased insulin sensitivity after a 
single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc 
fusion protein in obese insulin-resistant patients. J Clin Endocrinol Metab. 2000;85:1316-9. 
[77] Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-
TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with 
NIDDM. Diabetes. 1996;45:881-5. 
[78] Dominguez H, Storgaard H, Rask-Madsen C, Steffen Hermann T, Ihlemann N, 
Baunbjerg Nielsen D, et al. Metabolic and vascular effects of tumor necrosis factor-alpha 
blockade with etanercept in obese patients with type 2 diabetes. J Vasc Res. 2005;42:517-25. 
[79] Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab 
treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing 
spondylitis. Ann Rheum Dis. 2005;64:765-6. 
 









Figure 1. Adipose tissue inflammation in pathogenesis of metabolic syndrome and type 2 
diabetes 
Obesity induces adipocyte hypertrophy and changes in stromovascular cell composition with 
their phenotypic activation to a pro-inflammatory state. Cells from the adaptive immune 
system interact with adipose tissue macrophages to modify their activation state. In lean 
adipose tissue, T helper type 2 and regulatory T lymphocytes promote a M2 macrophage 
polarization, which maintain an anti-inflammatory state. Eosinophils may also induce a M2 
macrophage polarization. In obesity and type 2 diabetes, adipose tissue is characterized by an 
enrichment of macrophages and T lymphocytes with a shift from an anti-inflammatory to a 
pro-inflammatory state. Cytotoxic CD8+, T helper type 1 and T helper type 17 lymphocytes 
stimulate M1 macrophage polarization. Other cells, including B lymphocytes and mast cells, 
are also increased in obese adipose tissue and may contribute to obesity-induced 
inflammation. In obesity, the imbalance among immune cells results in production of 
chemokines and pro-inflammatory cytokines, which promote systemic inflammation and 
peripheral insulin resistance.  
Abbreviations: IL: interleukin; TNFα: tumor necrosis factor alpha; T2DM: type 2 diabetes mellitus; 
Treg : regulatory T lymphocytes. 
 
Figure 2. The NLRP3 inflammasome 
NLRP3 inflammasome is an intracellular multiprotein complex formed through the 
interaction of NLRP3, the protein adaptor ASC and the pro-caspase-1, leading to caspase-1 
activation. One activated, caspase-1 cleaves the inactive precursor of IL-1β (pro-IL-1β) into 
its biological active form which is secreted. NLRP3 activation requires a two-step process. 
First or “priming” signal acts on TLR or cytokines receptors and converges on the activation 
of NFκB pathway and transcriptional expression of inflammasome components, including 
NLRP3 and pro-IL-1β. The second or “activating” signal is then able to directly induce 
NLRP3 inflammasome formation and instigates caspase-1 activation. The second signal 
includes various PAMPs and DAMPs. 
Abbreviations: ASC: apoptosis-associated speck-like protein containing a caspase-recruitment 
domain; DAMPs: danger-associated molecular pattern; IL-1β : interleukin-1β ; NFκB : nuclear factor-
kappa B ; NLRP3 : nucleotide-binding oligomerization domain-like receptor family pyrin domain 
containing-3; PAMPs: pathogen-associated molecular patterns; TLR: toll-like receptor 
 
Figure legend(s)









Figure 3. Adipose tissue inflammatory profile imbalance between metabolically healthy 
and unhealthy obese 
Compared to metabolically healthy obesity (MHO) phenotype, the visceral adipose tissue of 
metabolically unhealthy obesity (MUO) phenotype is characterized by a higher NLRP3 
inflammasome activation in macrophages infiltrating visceral adipose tissue and a decrease 
number of anti-inflammatory regulatory T lymphocytes. This imbalance in the inflammatory 
profile may explain why metabolically healthy obese are at lower risk of developing type 2 
diabetes, NAFLD and cardiovascular diseases. The triggers that determine differential 
inflammasome activation remains to be identified. Fatty acids, glucose and uric acid may be 
good candidates. 
Abbreviations: MHO : metabolically healthy obesity; MUO: metabolically unhealthy obesity; 
NAFLD: nonalcoholic fatty liver disease; NLRP3 : nucleotide-binding oligomerization domain-like 
receptor family pyrin domain containing-3; T2DM: type 2 diabetes mellitus 
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